Moderna's Melanoma Data Are Solid. Wall Street Can't Agree What They're Worth.

Moderna drew two opposite verdicts from Wall Street this week, and neither one turned on the science. William Blair cut the stock to "Market Perform" from "Outperform" on Tuesday, citing valuation after a strong run. A day earlier, Piper Sandler had lifted its price target to $230 from $167 while keeping an "Overweight" rating, pointing to the INTerpath-001 results.

That split frames the real question for investors: whether the medical progress justifies more confidence, or whether the share price has already banked too much of it. The stock's recent gains don't settle the argument.

What the trial actually showed

The clinical foundation is substantial. Moderna and Merck reported last week that intismeran autogene combined with KEYTRUDA reduced the risk of melanoma recurrence or death by 42% versus KEYTRUDA alone. The reduction in the risk of distant metastasis or death came in at 38%.

At the presentation, Moderna put the recurrence-free survival rate at 24 months at 82.2% for intismeran plus pembrolizumab, against 70.0% for pembrolizumab on its own. Those figures make the treatment benefit easier to grasp than a single headline number about risk reduction.

The detailed Phase 3 data were presented at ESMO last week and published in The New England Journal of Medicine. The positive case therefore rests on concrete trial results rather than expectation alone. Even so, a risk reduction describes a clinical comparison. It is not a revenue forecast, nor a yardstick for how far a share price ought to travel.

Two houses, two readings of the same rally

The analyst actions diverge in emphasis rather than in their reading of the data. William Blair's downgrade was driven by valuation after the sharp climb, not by any dispute over the study findings. Piper Sandler's target hike rested on the INTerpath-001 results.

Notably, Piper Sandler's positive recommendation predated the target increase. A price target condenses one firm's view; it does not independently confirm every hope attached to a stock, and it does not answer how much optimism is already embedded in the quote.

Reuters reported a marked share decline after the detailed results were released — a reminder that a positive trial readout does not guarantee a positive market reaction. What investors had already priced in matters just as much. The scientific finding and its market valuation deserve separate judgments.

The next checkpoint

Moderna will report third-quarter 2026 results on November 6, 2026, and hold a conference call. That is the next scheduled event where the clinical narrative meets hard business numbers.

Until then, medical progress and its appropriate market price remain two distinct questions. If investors keep weighting the clinical evidence above valuation concerns, the optimistic case holds together. If worry about front-loaded expectations gains the upper hand, the recent recovery could come under pressure again. Either way, the trial data deserve weight — and the price targets deserve distance.